Synergy Pharmaceuticals to Present Study Results From Plecanatide Phase IIb/III Trial in Late-Breaking Clinical Abstract at Digestive Disease Week 2013

[at noodls] – NEW YORK, March 15, 2013 — Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that study results from the Phase IIb/III … more

View todays social media effects on SGYPW

View the latest stocks trending across Twitter. Click to view dashboard

See who Synergy is hiring next, click here to view